



Oncogenesis of Lymphoma

Guest Editors:

Dr. Annunziata Gloghini

Department of Diagnostic
Innovation, Fondazione IRCCS
Istituto Nazionale dei Tumori, Via
Venezian 1, 20133 Milan, Italy

Prof. Dr. Giancarlo Pruneri

Department of Diagnostic
Innovation, Fondazione IRCCS
Istituto Nazionale dei Tumori, Via
Venezian 1, 20133 Milan, Italy

Deadline for manuscript
submissions:

closed (20 May 2025)

Message from the Guest Editors

Dear Colleagues,

Advances in the fields of molecular genetics, immunology and virology have clarified the mechanisms involved in lymphomagenesis. Human lymphomas have been found to be heterogeneous, not only pathologically but also in terms of pathogenetic pathways, cellular derivation and the tumor microenvironment. Traditionally, some types of lymphomas are consistently correlated with genetic abnormalities involving *BCL2* and *BCL1*, respectively. It is well known that the molecular pathway in Burkitt lymphoma involves activation of *MYC*, inactivation of *p53* and infection by EBV. Furthermore, in diffuse large B-cell lymphomas (DLBCL), molecular studies have shown rearrangements in *BCL2*, *BCL6* and *MYC* genes. A new concept, viral cooperation, has been revealed in lymphomagenesis by molecular virologic studies on primary effusion lymphomas (PELs). In immune-deficient/dysregulated patients, PEL tumor cells, in addition to consistent infection by KSHV/HHV8, are also commonly infected by EBV. Finally, recent insights from genetics, epigenetics and knowledge in the cellular microenvironment have led to the refinement of diagnostic definition and, hopefully, appropriate therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)